Synthonics Inc. is at the forefront of developing Metal Coordinated Pharmaceuticals (MCPs), which leverage the medicinal properties of metal ions to enhance drug efficacy and absorption. The company has established itself as a leader in this innovative field, holding four active U.S. patents and numerous pending applications. MCPs utilize the unique electronic structures of transition metals, allowing for the fine-tuning of drug properties that are often unattainable with traditional organic compounds. This approach has demonstrated significant improvements in the absorption rates of various medications, including intravenous and over-the-counter products, thereby enhancing their therapeutic effectiveness.

The technology behind MCPs is rooted in the concept of chelating metals with known drugs to create novel compounds that exhibit superior pharmacokinetic profiles. For instance, Synthonics' first patent, issued in 2010, covers a complex of zinc with triiodothyronine (T3), marking a significant milestone in the patentability of these innovative molecules. The benefits of MCPs include higher efficacy, faster onset of action, and reduced variability in absorption, particularly for drugs that are less soluble. This cutting-edge approach positions Synthonics as a key player in the future of pharmaceutical development, with the potential to transform treatment options across a range of diseases.

United States

Synthonics, Inc. is a privately-held specialty pharmaceutical company focused on the discovery and development of patentable drugs that incorporate our proprietary metal coordination chemistry. We bind metals to known pharmaceutical agents to create new products that are better absorbed and thus have greater therapeutic benefits than their predecessors. Although our chemistry has broad application, we're preliminarily focused on drugs, such as T3 (liothyronine) and levodopa, whose short half-life limits their clinical utility.

Synthonics

Company Details